Jager et al. reported a patient diagnosed with metastatic NSCLC harboring a common EGFR mutation, a PIK3CA mutation, and CDK4 amplification, who benefited from combined osimertinib and palbociclib treatment after disease progression on osimertinib alone [26]. Here, PIK3CA is linked to non-small cell lung carcinoma.